Company Molecular Partners AG

Equities

MOLN

CH0256379097

Biotechnology & Medical Research

Market Closed - Swiss Exchange 12:30:28 2024-03-28 pm EDT 5-day change 1st Jan Change
3.675 CHF -3.03% Intraday chart for Molecular Partners AG +4.40% +6.83%

Business Summary

Molecular Partners AG is a Switzerland-based clinical-stage biotech company developing DARPin (Designed Ankyrin Repeat Proteins) a new class of custom-built protein therapeutics based on natural binding proteins that open a new dimension of multi-functionality and multi-target specificity in drug design. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.

Number of employees: 168

Sales per Business

CHF in Million2022Weight2023Weight Delta
Biopharmaceutical Products
100.0 %
190 100.0 % 7 100.0 % -96.29%

Sales per region

CHF in Million2022Weight2023Weight Delta
Switzerland
100.0 %
180 94.9 % 7 100.0 % -96.09%

Managers

Managers TitleAgeSince
Founder 52 04-11-22
Founder 49 04-11-22
Compliance Officer - 22-10-31
Chief Operating Officer - 22-06-30
Chief Tech/Sci/R&D Officer - 19-12-31
Chief Tech/Sci/R&D Officer - 10-12-31
Chief Tech/Sci/R&D Officer - 22-02-28
Investor Relations Contact - 19-10-31
Human Resources Officer - 21-09-30

Members of the board

Members of the board TitleAgeSince
Chairman 76 17-10-30
Director/Board Member 70 14-09-18
Director/Board Member 61 20-03-31
Founder 49 04-11-22
Director/Board Member 47 21-04-20
Director/Board Member 61 20-04-28
Director/Board Member 53 20-03-31
Director/Board Member 57 21-04-20

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 36,368,901 29,497,085 ( 81.11 %) 3,500,000 ( 9.624 %) 81.11 %

Shareholders

NameEquities%Valuation
BVF Partners LP
23.91 %
8,696,205 23.91 % 39 M CHF
Suvretta Capital Management LLC
4.812 %
1,750,000 4.812 % 8 M CHF
1,739,130 4.782 % 8 M CHF
EcoR1 Capital, LLC
2.989 %
1,086,993 2.989 % 5 M CHF
1,077,737 2.963 % 5 M CHF
GAM Investment Management (Switzerland) AG
2.935 %
1,067,288 2.935 % 5 M CHF
767,524 2.110 % 3 M CHF
735,095 2.021 % 3 M CHF
Union Bancaire Privée, UBP SA
1.162 %
422,754 1.162 % 2 M CHF
ACATIS Investment Kapitalverwaltungsgesellschaft mbH
0.5501 %
200,070 0.5501 % 887 256 CHF
NameEquities%Valuation
BVF, Inc.
1.219 %
443,221 1.219 % 2 M CHF
Suvretta Capital Management LLC
1.100 %
400,000 1.100 % 2 M CHF
Tang Capital Management LLC
0.2750 %
100,000 0.2750 % 448 500 CHF
G1 Execution Services LLC
0.0347 %
12,618 0.0347 % 56 592 CHF
Morgan Stanley Capital Services LLC
0.001009 %
367 0.001009 % 1 646 CHF
RhumbLine Advisers LP
0.000740 %
269 0.000740 % 1 206 CHF
Qube Research & Technologies Ltd. (France)
0.000044 %
16 0.000044 % 72 CHF
JPMorgan Securities LLC
0.000003 %
1 0.000003 % 4 CHF

Company contact information

Molecular Partners AG

Wagistrasse 14

8952, Schlieren

+41 44 755 77 00

http://www.molecularpartners.com
address Molecular Partners AG(MOLN)

Sales per region

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
3.675 CHF
Average target price
9.5 CHF
Spread / Average Target
+158.50%
Consensus

Quarterly revenue - Rate of surprise